Table 3.

Estimated risk of venous thromboembolism events (VTE) with combined oral contraceptives (COC).

Risk group	Estimated risk of VTE	Reference
Non-pregnant non-user	2/10 000 WY	EMA/739865/2013 (84)
Pregnant and postpartum women	20/10 000 WY	30-year population-based study (85)
User of COC containing - EE + LNG - EE + NETA - EE + NGM	5-7/10 000 WY	EMA/739865/2013 (84)
User of COC containing - EE + GSD - EE+ DSG - EE+ DRSP	9-12/10 000 WY	EMA/739865/2013 (84)
User of COC containing - EE + CMA	Unknown	N/A
User of COC containing - EE + DNG	8-11/10 000 WY (update from the EMA)	EMA
User of COC containing - E2V + DNG	7.0/10 000 WY versus 3.5 in non-user and 9.9 in LNG/EE users	INAS-SCORE study (82)
User of COC containing - E2/NOMAC	2.0/10 000 WY versus 1.8 in non-user and 3.0 in LNG/EE users	PRO-E2 (83)
User of COC containing - E4/DRSP	Pending	PASS required by the EMA and FDA

CMA, chlormadinone acetate; COC, combined oral contraceptives; DNG, dienogest; DRSP, drospirenone; DSG, desogestrel; EE, ethinylestradiol; EMA, European Medicines Agency; EURAS, European Actie Surveillance Study; E2, 17β-estradiol; E2V, estradiol valerate; E4, estetrol; GSD, gestodene; INAS-CELINA, International Active Surveillance Study: Choice of Estrogen and Long-term Investigation of Nomegestrol Acetate; INAS-SCORE, International Active Surveillance study “Safety of Contraceptives: Role of Estrogens”; LNG, levonorgestrel; NETA, norethisterone acetate; NGM, norgestimate; PASS, post authorization safety study; VTE, venous thromboembolism; WY, women-year. N/A, not applicable.